Abstract 4951
Background
PD-1 blockade monoclonal antibodies, nivolumab and pembrolizumab, increase quality of life and overall survival of metastatic melanoma and are today’s first-line treatment of metastatic melanoma. Nevertheless, only 40% of the patients will respond to anti-PD-1 monotherapy. In the era of personalized medicine, an important stake is to identify the patients who will benefit from these treatments, which are also responsible for scare but serious side effects. We have tested several biomarkers to discriminate between responders and non-responders.
Methods
We have retrospectively analysed 18 patients treated by pembrolizumab for metastatic melanoma. Immunohistochemical staining was performed on pre-treatment metastatic tissue for antigens such as MELANA, TYR, GP100, PD-L1, CD3, CD8, IDO1, HLA class I heavy chain and β2-microglobulin. Two reviewers assessed the staining independently. For PD-L1 testing, the MEL-score was used. For T-cell infiltration, we have quoted the presence of CD3 CD8 T cell and their location.
Results
We found that only PD-L1 expression and the presence of T-cell infiltration were associated with a better response to pembrolizumab: PD-L1 expression (p = 0,043), T-cell infiltration (p = 0,025) and T-cell location at the periphery of the tumoral nodules (p = 0,025). PD-L1 expression and the presence of T lymphocytes were also associated with a longer survival. The median overall survival was 31,5 months for the T-cell rich metastasis and PD-L1 high expression versus 4 months for non T-cell infiltrated tumours and 7 months for PD-L1 negative tumours. Furthermore, 50% of the metastases showed reduced or absent HLA class I expression by the tumour cells. The role of tumoral HLA loss in response and resistance to PD-1 blockade has still to be defined.
Conclusions
Although significant correlations were observed between some biomarkers and the response to anti-PD-1 therapy as described in larger studies, no predictive biomarker has currently been identified in our small series. Recent and future technical progresses will enable new studies aiming to find reliable biomarkers and to clarify the complex mechanisms of response and resistance to immune checkpoint inhibitors.
Clinical trial identification
Legal entity responsible for the study
Cliniques universitaires Saint-Luc.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract